XENT Stock Performance, Insider Transaction and News

XENT - Intersect ENT, Inc.

Market Cap	0.95B	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-159.64M	Forward P/E	-25.44	EPS next Y	-	50D Avg Chg	1.00%
Sales	106.75M	PEG	-	EPS past 5Y	-	200D Avg Chg	3.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	7.60%	52W High Chg	-
Recommedations	3.00	Quick Ratio	1.37	Shares Outstanding	33.79M	52W Low Chg	77.00%
Insider Own	1.50%	ROA	-23.28%	Shares Float	27.59M	Beta	1.53
Inst Own	92.34%	ROE	-	Shares Shorted/Prior	2.87M/2.59M	Price	28.24
Gross Margin	71.89%	Profit Margin	-149.54%	Avg. Volume	414,536	Target Price	28.25
Oper. Margin	-65.30%	Earnings Date	May 9	Volume		Change	0.00%

Healthcare | Medical Devices | United States

About Intersect ENT, Inc.

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.

XENT Chatroom

kellyCriterion101 Posted - 6 months ago

$tmci here's the issue with this co. this co has had offers on the table but always wanted more money. I think they have an offer now, and unfortunately need to "show me" the story after the Q1 blunder. the company has cash issues if it doesn't fix things. but the r/R is incredible on a valuation perspective. I think Stryker buys out Treace before 2024 wraps up for 8-10 a share. My guess, November. I own leaps and common equity. It's nice to see management put their money where their mouth is. They just bought over 2%+ of the float, possibly more filings will come (waiting on the CFO and Director of Sales). I saw similar things when $XENT flopped a quarter. The biggest things that cause these sinks are operating margin guides because a small move up or down, can be detrimental to the stock. They need to "bridge" the guide down back up. I'll put together a full model when I get time but I won't bet the farm here.

risenhoover Posted - 03/26/23

$XENT XENT / Intersect ENT Inc Price Target Updated https://fintel.io/sfo/us/xent?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$XENT XENT / Intersect ENT Inc Price Target Updated https://fintel.io/sfo/us/xent?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/24/23

$XENT XENT / Intersect ENT Inc Price Target Updated https://fintel.io/sfo/us/xent?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/23/23

$XENT XENT / Intersect ENT Inc Price Target Updated https://fintel.io/sfo/us/xent?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget